BioXcel Therapeutics (BTAI) Misses Q4 EPS by 58c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q4 EPS of ($0.58). Revenue for the quarter came in at $260 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Pacific Booker Minerals Inc. Adopts Advance Notice Policy for Director Elections
• U.S. presses Meta to agree to A.I. reviews as security concerns rise - NYT